GenVec Financial Statements
GenVec Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
GenVec Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 14.1 | 18.9 | 26.5 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (21.3) | (20.3) | (14.5) |
| Total Net Income ($ mil.) | (18.7) | (19.3) | (14.0) |
| Diluted EPS (Net Income) | (0.25) | (0.30) | (0.24) |
GenVec Quarterly Statements
| Quarter Ending Jun 08 | Quarter Ending Mar 08 | Quarter Ending Dec 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 3.9 | 3.7 | 3.7 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (6.8) | (6.4) | (5.6) |
| Total Net Income ($ mil.) | (6.6) | (6.3) | (4.4) |
| Diluted EPS (Net Income) | (0.09) | (0.08) | (0.06) |
GenVec Stock Quote & Chart
10/07/08 14:59:59 EST •
NASDAQ •
1.04
•
 -0.0100
•
-0.9524 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
GenVec Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 7.29 | 3.66 | 1.55 |
| Price/Earnings Ratio | -- | 15.34 | 15.75 |
| Price/Book Ratio | 4.35 | 2.93 | 1.49 |
| Price/Cash Flow Ratio | -- | 12.16 | 9.68 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed GenVec Financial Ratios
GenVec Competitive Intelligence
| Ark Therapeutics Group | Introgen Therapeutics | Schering-Plough | |
|---|---|---|---|
| Annual Sales ($ mil.) | 1.1 | 1.0 | 12,690.0 |
| Employees | 152 | -- | 55,000 |
| Market Cap ($ mil.) | -- | 38.7 | 32,999.5 |
Competitive Landscape
